Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track

Cocrystal Pharma, Inc.

2024-Q1 EPS reported -$0.39

Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.
Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.
Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.
Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cocrystal Pharma, Inc. reported financial results for Q1 2024.

Period: Q1 2024
Result: reported results

Exact text from the filing

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018798

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.